{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:00:37Z","timestamp":1792803637745,"version":"4.5.0"},"reference-count":51,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Else Kr\u00f6ner-Fresenius-Stiftung (EKFS)","award":["Else Kr\u00f6ner-Promotionskolleg Dresden"],"award-info":[{"award-number":["Else Kr\u00f6ner-Promotionskolleg Dresden"]}]},{"name":"Else Kr\u00f6ner-Fresenius-Stiftung (EKFS)","award":["#70112014"],"award-info":[{"award-number":["#70112014"]}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["Else Kr\u00f6ner-Promotionskolleg Dresden"],"award-info":[{"award-number":["Else Kr\u00f6ner-Promotionskolleg Dresden"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["#70112014"],"award-info":[{"award-number":["#70112014"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The IDH1R132H mutation in glioma results in the neoenzymatic function of IDH1, leading to the production of the oncometabolite 2-hydroxyglutarate (2-HG), alterations in energy metabolism and changes in the cellular redox household. Although shifts in the redox ratio NADPH\/NADP+ were described, the consequences for the NAD+ synthesis pathways and potential therapeutic interventions were largely unexplored. Here, we describe the effects of heterozygous IDH1R132H on the redox system in a CRISPR\/Cas edited glioblastoma model and compare them with IDH1 wild-type (IDH1wt) cells. Besides an increase in 2-HG and decrease in NADPH, we observed an increase in NAD+ in IDH1R132H glioblastoma cells. RT-qPCR analysis revealed the upregulation of the expression of the NAD+ synthesis enzyme nicotinamide phosphoribosyltransferase (NAMPT). Knockdown of NAMPT resulted in significantly reduced viability in IDH1R132H glioblastoma cells. Given this dependence of IDH1R132H cells on NAMPT expression, we explored the effects of the NAMPT inhibitors FK866, GMX1778 and GNE-617. Surprisingly, these agents were equally cytotoxic to IDH1R132H and IDH1wt cells. Altogether, our results indicate that targeting the NAD+ synthesis pathway is a promising therapeutic strategy in IDH mutant gliomas; however, the agent should be carefully considered since three small-molecule inhibitors of NAMPT tested in this study were not suitable for this purpose.<\/jats:p>","DOI":"10.3390\/ijms23105787","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T09:18:08Z","timestamp":1653124688000},"page":"5787","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model"],"prefix":"10.3390","volume":"23","author":[{"given":"Maximilian","family":"Clausing","sequence":"first","affiliation":[{"name":"Institute for Clinical Genetics, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, 01307 Dresden, Germany"},{"name":"National Center for Tumor Diseases Partner Site Dresden (NCT\/UCC), German Cancer Consortium (DKTK), 01307 Dresden, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7824-5073","authenticated-orcid":false,"given":"Doreen","family":"William","sequence":"additional","affiliation":[{"name":"Institute for Clinical Genetics, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, 01307 Dresden, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases (NCT\/UCC), German Cancer Consortium (DKTK), 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Preussler","sequence":"additional","affiliation":[{"name":"Institute for Clinical Genetics, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, 01307 Dresden, Germany"},{"name":"National Center for Tumor Diseases Partner Site Dresden (NCT\/UCC), German Cancer Consortium (DKTK), 01307 Dresden, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Biedermann","sequence":"additional","affiliation":[{"name":"Institute for Clinical Genetics, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8942-0287","authenticated-orcid":false,"given":"Konrad","family":"Gr\u00fctzmann","sequence":"additional","affiliation":[{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases (NCT\/UCC), German Cancer Consortium (DKTK), 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3549-2477","authenticated-orcid":false,"given":"Susan","family":"Richter","sequence":"additional","affiliation":[{"name":"Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4577-3344","authenticated-orcid":false,"given":"Frank","family":"Buchholz","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases Partner Site Dresden (NCT\/UCC), German Cancer Consortium (DKTK), 01307 Dresden, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"Medical Systems Biology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-1180","authenticated-orcid":false,"given":"Achim","family":"Temme","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases Partner Site Dresden (NCT\/UCC), German Cancer Consortium (DKTK), 01307 Dresden, Germany"},{"name":"Section Experimental Neurosurgery\/Tumor Immunology, Department of Neurosurgery, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin","family":"Schr\u00f6ck","sequence":"additional","affiliation":[{"name":"Institute for Clinical Genetics, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, 01307 Dresden, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases (NCT\/UCC), German Cancer Consortium (DKTK), 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8753-8238","authenticated-orcid":false,"given":"Barbara","family":"Klink","sequence":"additional","affiliation":[{"name":"Institute for Clinical Genetics, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, 01307 Dresden, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases (NCT\/UCC), German Cancer Consortium (DKTK), 01307 Dresden, Germany"},{"name":"National Center of Genetics (NCG), Laboratoire National de Sant\u00e9 (LNS), L-3555 Luxembourg, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-319-12048-5_2","article-title":"Glioma biology and molecular markers","volume":"163","author":"Cohen","year":"2015","journal-title":"Cancer Res. Treat."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Rath, B.H., Fair, J.M., Jamal, M., Camphausen, K., and Tofilon, P.J. (2013). Astrocytes Enhance the Invasion Potential of Glioblastoma Stem-Like Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054752"},{"key":"ref_3","first-page":"7","article-title":"Ten-year survival in glioblastoma. A systematic review","volume":"54","author":"Tykocki","year":"2018","journal-title":"J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpubh.2016.00151","article-title":"Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry","volume":"4","author":"Chien","year":"2016","journal-title":"Front. Public Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11910-013-0345-4","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"13","author":"Cohen","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 Mutations in Gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/ng.223","article-title":"Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle","volume":"40","author":"Hartong","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/neuonc\/nov136","article-title":"Isocitrate dehydrogenase mutations in gliomas","volume":"18","author":"Waitkus","year":"2016","journal-title":"Neuro. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of \u03b1-Ketoglutarate-Dependent Dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature10898","article-title":"Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation","volume":"483","author":"Koivunen","year":"2013","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s13277-014-2644-z","article-title":"Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation","volume":"36","author":"Shi","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1007\/s13277-014-1784-5","article-title":"Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation","volume":"35","author":"Ohka","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.15252\/emmm.201707729","article-title":"Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways","volume":"9","author":"Fack","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Biedermann, J., Preussler, M., Conde, M., Peitzsch, M., Richter, S., Wiedemuth, R., Abou-El-Ardat, K., Kr\u00fcger, A., Meinhardt, M., and Schackert, G. (2019). Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. Cancers, 11.","DOI":"10.3390\/cancers11122028"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-010-0645-6","article-title":"The prognostic IDH1R132mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma","volume":"119","author":"Bleeker","year":"2010","journal-title":"Acta Neuropathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ccell.2015.11.006","article-title":"Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion","volume":"28","author":"Tateishi","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MOG.0b013e32801b3c8f","article-title":"The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt\/PBEF\/visfatin in mammals","volume":"23","author":"Revollo","year":"2007","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1593\/neo.131718","article-title":"Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models","volume":"15","author":"Oeh","year":"2013","journal-title":"Neoplasia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1128\/MCB.00112-09","article-title":"The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: Strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors","volume":"29","author":"Watson","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1593\/neo.131304","article-title":"Dependence of Tumor Cell Lines and Patient-Derived Tumors on the NAD Salvage Pathway Renders Them Sensitive to NAMPT Inhibition with GNE-618","volume":"15","author":"Xiao","year":"2013","journal-title":"Neoplasia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4161\/cbt.7.5.5663","article-title":"PBEF1\/NAmPRTase\/Visfatin: A potential malignant astrocytoma\/glioblastoma serum marker with prognostic value","volume":"7","author":"Reddy","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601913507576","article-title":"Nicotinamide Phosphoribosyltransferase in Malignancy: A Review","volume":"4","author":"Shackelford","year":"2013","journal-title":"Genes Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pharmthera.2015.02.004","article-title":"Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer","volume":"151","author":"Sampath","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00401-017-1671-4","article-title":"Glioma: Experimental models and reality","volume":"133","author":"Lenting","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/bjc.2011.27","article-title":"Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions","volume":"104","author":"Piaskowski","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00401-020-02226-7","article-title":"Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology","volume":"140","author":"Golebiewska","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Klink, B., Miletic, H., Stieber, D., Huszthy, P.C., Valenzuela, J.A.C., Balss, J., Wang, J., Schubert, M., Sakariassen, P.\u00d8., and Sundstr\u00f8m, T. (2013). A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1. PLoS ONE, 8.","DOI":"10.1371\/annotation\/72a01ce5-b0ad-4cbd-ac77-0a81347a3940"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/neuonc\/nor098","article-title":"RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo","volume":"13","author":"Hendruschk","year":"2011","journal-title":"Neuro. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhu, H., Zhang, Y., Chen, J., Qiu, J., Huang, K., Wu, M., and Xia, C. (2017). IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169038"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1158\/0008-5472.CAN-14-3603","article-title":"Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198","volume":"75","author":"Molenaar","year":"2015","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/cr.2013.73","article-title":"Differentiation therapy for IDH1\/2 mutant malignancies","volume":"23","author":"Melnick","year":"2013","journal-title":"Cell Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11060-019-03359-w","article-title":"Extracellular glutamate and IDH1(R132H) inhibitor promote glioma growth by boosting redox potential","volume":"146","author":"Tiburcio","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrc3340","article-title":"The NAD metabolome\u2014A key determinant of cancer cell biology","volume":"12","author":"Chiarugi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"E8247","DOI":"10.1073\/pnas.1610921114","article-title":"An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma","volume":"113","author":"Gujar","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"99514","DOI":"10.18632\/oncotarget.20577","article-title":"NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis","volume":"8","author":"Carnero","year":"2017","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41467-017-00984-9","article-title":"Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL","volume":"8","author":"Ishida","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.metabol.2018.01.001","article-title":"The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges","volume":"82","author":"Dalamaga","year":"2018","journal-title":"Metabolism"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bowlby, S.C., Thomas, M.J., D\u2019Agostino, R.B., and Kridel, S.J. (2012). Nicotinamide Phosphoribosyl Transferase (Nampt) Is Required for De Novo Lipogenesis in Tumor Cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040195"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"22408","DOI":"10.1074\/jbc.M112.357301","article-title":"Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates Reactive Oxygen Species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner","volume":"287","author":"Cerna","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1450843","DOI":"10.1155\/2016\/1450843","article-title":"Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS\/JNK Signaling Pathway","volume":"2016","author":"Feng","year":"2016","journal-title":"BioMed. Res. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00018-012-1249-1","article-title":"Intracellular NAD(H) levels control motility and invasion of glioma cells","volume":"70","author":"Willemse","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_45","first-page":"7436","article-title":"FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis","volume":"63","author":"Hasmann","year":"2003","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1074\/jbc.M112.394510","article-title":"Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+biosynthesis, in human cancer cells: Metabolic basis and potential clinical implications","volume":"288","author":"Tan","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lfs.2017.08.027","article-title":"RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials","volume":"188","year":"2017","journal-title":"Life Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1700072","DOI":"10.1002\/smll.201700072","article-title":"A Poly(Propyleneimine) Dendrimer-Based Polyplex-System for Single-Chain Antibody-Mediated Targeted Delivery and Cellular Uptake of SiRNA","volume":"13","author":"Tietze","year":"2017","journal-title":"Small"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2017.07.001","article-title":"Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases","volume":"262","author":"Albuquerque","year":"2017","journal-title":"J. Contr. Release"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C T method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5787\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:16:10Z","timestamp":1760138170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijms23105787"],"URL":"https:\/\/doi.org\/10.3390\/ijms23105787","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]}}}